Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Axis Direct

Biocon Ltd.

NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

337.20 3.20 (0.96%)

25.10% Gain from 52W Low

3.3M NSE+BSE Volume

NSE 03 Jun, 2025 3:31 PM (IST)

40,484.2

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

Regulatory Approval

Biocon receives CDSCO nod for Liraglutide, used to treat Type 2 diabetes in adults and children See details

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	4453.90	3856.20	3965.70	15.5%	12.3%
Operating Profit Qtr	1078.20	751.80	915.90	43.4%	17.7%
Net Profit Qtr	344.50	25.10	135.50	1272.5%	154.2%
Earning Per Share Adjusted latest Qtr	2.87	0.21	1.13	1266.7%	154.0%

Biocon Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.